Skip to main content

Table 2 Predictors of experiencing comorbid conditions during the 12 months follow-up after down-referral or eligibility

From: Effective public-private partnerships for sustainable antiretroviral therapy: outcomes of the Right to Care health services GP down-referral program

 Experienced comorbid conditions n (%)Person-yearsRate per 100 person-years (95% CI)cHR (95% CI)
96 (2.6)2888.23.3 (2.7–4.1) 
Study cohort
 GP down-referred7 (1.9)368.71.9 (0.9–4.0)1
 Clinic A controls70 (2.7)2011.83.5 (2.8–4.4)2.0 (0.9–4.2)
 Clinic B controls19 (2.7)507.63.7 (2.4–5.9)2.2 (0.9–5.3)
Sex
 Female70 (2.9)1900.83.7 (2.9–4.7)1
 Male26 (2.1)987.42.6 (1.8–3.9)0.7 (0.5–1.1)
Age at down-referral/eligibility (years)
 18–29.996 (1.4)348.71.7 (0.8–3.8)1
 30–39.9937 (2.4)1195.43.1 (2.2–4.3)1.8 (0.8–4.3)
 40–49.9938 (3.1)940.54.0 (2.9–5.5)2.4 (0.9–5.6)
 50+15 (2.9)403.63.7 (2.2–6.2)2.2 (0.8–5.6)
Nationality
 South African82 (2.5)2548.33.2 (2.6–4.0)1
 Non-South African14 (3.6)339.84.1 (2.4–7.0)1.2 (0.7–2.2)
Education level
 Primary school or less16 (2.4)519.93.1 (0.9–5.0)1.0 (0.6–1.8)
 Some secondary school30 (3.7)711.24.2 (2.9–6.0)1.3 (0.8–2.2)
  > =Grade 1241 (2.4)1352.43.0 (2.2–4.1)1
Employment status
 Employed49 (2.6)1509.03.2 (2.5–4.3)1
 Unemployed42 (2.4)1322.43.2 (2.3–4.3)1.0 (0.7–1.5)
Time on ART at down-referral/eligibility (years)
 1–2.9 year54 (2.9)1526.83.5 (2.7–4.6)1
 3–4.9 years18 (1.9)713.02.5 (1.6–4.0)0.7 (0.4–1.2)
  > =5 years24 (2.7)648.33.7 (2.5–5.5)1.1 (0.7–1.8)
Guideline year of ART initiation
 2004–201049 (2)1832.52.7 (2.0–3.5)1
 2011–201447 (3.6)1055.74.5 (3.3–5.9)0.6 (0.4–0.9)
Baseline CD4 (cells/μl)
 250–349.930 (2.9)852.93.5 (2.5–5.0)1.3 (0.8–2.2)
 350–499.938 (3.1)968.13.9 (2.9–5.4)1.5 (0.9–2.4)
  > =50028 (1.9)1067.12.6 (1.8–3.8)1
Baseline VL (copies/mL)
  < 5061 (2.7)1750.73.5 (2.7–4.5)1
 50–19923 (2.5)715.33.2 (2.1–4.8)0.9 (0.6–1.5)
 200–39911 (2.1)421.12.6 (1.4–4.7)0.8 (0.4–1.4)
Baseline BMI (kg/m2)
 Normal46 (3)1297.03.5 (2.7–4.7)1
 Overweight20 (2.4)706.62.8 (1.8–4.4)0.8 (0.5–1.4)
 Obese17 (3.4)4114.1 (2.6–6.7)1.2 (0.7–2.0)
ART regimen
 TDF + 3TC/FTC + EFV/NVP47 (3.7)1036.94.5 (3.4–6.0)1
 AZT + 3TC + EFV/NVP4 (2.1)151.62.6 (1.0–7.0)0.6 (0.2–1.6)
 d4T + 3TC + EFV/NVP43 (2)1666.52.6 (1.9–3.5)0.6 (0.4–0.9)
12 month Retention
 Alive and in care81 (3.3)2300.33.5 (2.8–4.4)1
 LTFU5 (1.7)175.32.9 (1.2–6.7)1.1 (0.5–2.5)
 Deceased4 (12.1)10.239.3 (14.7)18.0 (6.3–50.6)
 Transferred out6 (0.6)401.41.5 (0.7–3.3)0.5 (0.2–1.3)
  1. HR, hazard ratio, cHR, crude hazard ratio, 95% CI, 95% confidence interval, PY, person-years